{
    "nct_id": "NCT05380349",
    "official_title": "A Phase 1 Study of Combination Drug Therapy Based on Personalized Cancer Stem Cell (CSC) High-Throughput Drug Screening (HTS) With Standard of Care for Newly Diagnosed Glioblastoma",
    "inclusion_criteria": "* Histological diagnosis of GBM (WHO grade 4)\n* Subjects ≥18 years of age\n* Patients must have a life expectancy of >6 months\n* Patients must have a surgically accessible tumor with the intent for a gross or near total resection of the tumor mass (GBM, WHO grade 4)\n* Patients must have a KPS rating of ≥70\n* Patients should not have received any prior systemic anti-cancer therapy\n* Patients must be negative for HIV, Hepatitis B and C\n* Baseline hematologic studies and chemistry and coagulation profiles must meet the following criteria:\n\n  * Hemoglobin (Hgb)> 8 g/dL\n  * Absolute Neutrophil Count (ANC) > 1,000/mm3\n  * Platelet count > 100,000/mm3\n  * Creatinine < 2 mg/dL\n  * Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) < 3x upper limit of normal (ULN)\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Metastatic disease\n* Diseases or conditions that obscure toxicity or dangerously alter drug metabolism\n* Serious intercurrent medical illness\n* Inadequately controlled hypertension\n* History of myocardial infarction or unstable angina within 6 months\n* History of stroke or transient ischemic attack within 6 months",
    "miscellaneous_criteria": ""
}